Private equity consortium/Par Pharmaceutical

Target: Par Pharmaceutical
Buyer: Private equity consortium
Price: $1.9 billion
Closed: Sept. 28, 2012

This deal started when activist investor Ralph Whitworth decided the generics maker was worth a lot more than its valuation indicated. His Relational Investors increased its stake in Par, then told it to park itself on a corner with a For Sale sign in the window.

The company quickly picked up an offer. The Texas-based private equity group TPG agreed to pay $50 per share, a 37% premium, putting a total value of $1.9 billion on the company. Par wanted a couple of months to see if other buyers would check it out, and about 40 kicked the tires of the generics maker. Three even signed confidentiality agreements to get a closer look. But in the end, no auction materialized. TPG walked away with Par and Whitworth with some extra cash.

Private equity consortium/Par Pharmaceutical

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.